Spots Global Cancer Trial Database for liver transplant; complications
Every month we try and update this database with for liver transplant; complications cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Liver Transplantation for Unresectable GIST Liver Metastases | NCT04825470 | Liver Diseases Liver Cancer Liver Metastase... Liver Neoplasms Liver Mass Liver Carcinoma Liver Transplan... Liver Transplan... GIST GIST, Malignant Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Metastases to L... Metastatic Live... Metastasis Metastases Liver Transplan... Transplant Onco... | Liver Transplan... | 18 Years - | Hospital Universitario Virgen de la Arrixaca | |
| Liver Transplantation for Unresectable GIST Liver Metastases | NCT04825470 | Liver Diseases Liver Cancer Liver Metastase... Liver Neoplasms Liver Mass Liver Carcinoma Liver Transplan... Liver Transplan... GIST GIST, Malignant Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Gastrointestina... Metastases to L... Metastatic Live... Metastasis Metastases Liver Transplan... Transplant Onco... | Liver Transplan... | 18 Years - | Hospital Universitario Virgen de la Arrixaca | |
| Influence of Intraoperative Blood Salvage and Autotransfusion on Tumor Recurrence After Deceased Donor Liver Transplantation | NCT06307158 | Liver Transplan... | 18 Years - 80 Years | Zhejiang University | ||
| Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | NCT06041490 | Liver Transplan... Hepatocarcinoma Recurrent Osteo... High-Risk Cance... | multi-kinase in... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Liver Transplantation After ex Vivo Liver Perfusion | NCT05951231 | Liver Transplan... Transplant; Fai... Transplant Dysf... Transplant; Com... Transplant Liver Metastase... Liver Cancer | Liver transplan... | 18 Years - 100 Years | Oslo University Hospital | |
| Prehabilitation and Posttransplant Training Program in Liver Transplantation | NCT04246970 | Liver Transplan... Cirrhosis, Live... Hepatic Carcino... | Prehabilitation Prehabilitation... | 18 Years - | Hospital Universitario La Fe | |
| Prehabilitation and Posttransplant Training Program in Liver Transplantation | NCT04246970 | Liver Transplan... Cirrhosis, Live... Hepatic Carcino... | Prehabilitation Prehabilitation... | 18 Years - | Hospital Universitario La Fe | |
| Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | NCT06041490 | Liver Transplan... Hepatocarcinoma Recurrent Osteo... High-Risk Cance... | multi-kinase in... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) | NCT04443322 | Liver Carcinoma Liver Transplan... | Durvalumab Inje... Lenvatinib 4 MG | 18 Years - 80 Years | RenJi Hospital | |
| Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant | NCT04425226 | Liver Transplan... Hepatocellular ... | Pembrolizumab I... Lenvatinib Oral... | 18 Years - 80 Years | RenJi Hospital | |
| Outcome Analysis of Aspirin in Liver Transplantation | NCT04327427 | Liver Transplan... | Aspirin | 18 Years - | University of Zurich | |
| Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence | NCT04506398 | Hepatocellular ... Liver Transplan... | liver transplan... ctDNA whole exome seq... | 18 Years - 80 Years | RenJi Hospital | |
| HHV8 and Solid Organ Transplantation | NCT05081141 | HHV8 HHV8 Infection HHV8-Related Ma... Kaposi Sarcoma Lung Transplant... Liver Transplan... Kidney Transpla... Castleman Disea... | Diagnostic test... | 18 Years - | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |
| Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation | NCT03946852 | Liver Transplan... Ischemia Reperf... Cirrhosis Liver Cancer Liver Metastase... End Stage Liver... | Abdominal Regio... | 18 Years - 75 Years | London Health Sciences Centre | |
| Prehabilitation and Posttransplant Training Program in Liver Transplantation | NCT04246970 | Liver Transplan... Cirrhosis, Live... Hepatic Carcino... | Prehabilitation Prehabilitation... | 18 Years - | Hospital Universitario La Fe | |
| IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | NCT05339581 | Liver Cancer Liver Transplan... Hepatocellular ... Portal Vein Thr... Radiotherapy; C... | intensity-modul... Pembrolizumab Sintilimab Camrelizumab Tislelizumab Lenvatinib Mesy... | 18 Years - 80 Years | RenJi Hospital | |
| IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | NCT05339581 | Liver Cancer Liver Transplan... Hepatocellular ... Portal Vein Thr... Radiotherapy; C... | intensity-modul... Pembrolizumab Sintilimab Camrelizumab Tislelizumab Lenvatinib Mesy... | 18 Years - 80 Years | RenJi Hospital | |
| Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) | NCT04443322 | Liver Carcinoma Liver Transplan... | Durvalumab Inje... Lenvatinib 4 MG | 18 Years - 80 Years | RenJi Hospital | |
| Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular Carcinoma | NCT06114251 | Liver Transplan... | Diagnosis of po... | 18 Years - 75 Years | Zhejiang University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
